Target type: biologicalprocess
The process whose specific outcome is the formation of tooth enamel, occurring in two stages: secretory stage and maturation stage. [GOC:cjm, GOC:sl, PMID:10206335, PMID:21196346]
Amelogenesis is the process of forming enamel, the hard, outermost layer of teeth. This complex process begins during tooth development and involves the coordinated interplay of specialized cells, proteins, and minerals.
1. **Initiation:** The process starts with the differentiation of ameloblasts, specialized cells responsible for enamel formation. These cells originate from the enamel organ, an epithelial structure surrounding the developing tooth.
2. **Secretory Stage:** Ameloblasts begin secreting enamel matrix proteins, primarily amelogenin, enamelin, and tuftelin. These proteins act as a scaffold for the deposition of hydroxyapatite crystals, the primary mineral component of enamel.
3. **Maturation Stage:** As ameloblasts secrete enamel proteins, they gradually move away from the enamel surface, leaving behind a layer of enamel matrix. During the maturation stage, ameloblasts modify the enamel matrix by removing proteins and promoting the growth and organization of hydroxyapatite crystals. This process results in the formation of highly organized and densely packed enamel crystals, giving enamel its exceptional hardness and resistance to wear.
4. **Mineralization:** The deposition of hydroxyapatite crystals within the enamel matrix is a tightly regulated process. The ameloblasts control the concentration of calcium and phosphate ions in the enamel matrix, ensuring the proper formation of crystals.
5. **Final Enamel Formation:** After the maturation stage, ameloblasts become flattened and form a thin layer called the enamel cuticle. The enamel cuticle helps to protect the underlying enamel from damage and serves as a barrier against bacteria.
Amelogenesis is a highly regulated and intricate process that requires the coordinated activity of multiple genes and cellular signaling pathways. Disruptions in these processes can lead to various enamel defects, such as hypoplasia, hypomineralization, and enamel dysplasia. These defects can affect the strength and appearance of teeth, leading to increased susceptibility to caries and other dental problems.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Kallikrein-5 | A kallikrein-5 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9Y337] | Homo sapiens (human) |
| Matrix metalloproteinase-20 | A matrix metalloproteinase-20 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60882] | Homo sapiens (human) |
| Kallikrein-4 | A kallikrein-4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9Y5K2] | Homo sapiens (human) |
| Sodium/potassium/calcium exchanger 4 | A sodium/potassium/calcium exchanger 4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8NFF2] | Homo sapiens (human) |
| Cystic fibrosis transmembrane conductance regulator | A cystic fibrosis transmembrane conductance regulator that is encoded in the genome of human. [PRO:CNA, UniProtKB:P13569] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| glyburide | glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group. Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide | monochlorobenzenes; N-sulfonylurea | anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent |
| potassium chloride | potassium chloride : A metal chloride salt with a K(+) counterion. Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA. | inorganic chloride; inorganic potassium salt; potassium salt | fertilizer |
| methyl anthranilate | methyl anthranilate : A benzoate ester that is the methyl ester of anthranilic acid. | benzoate ester | flavouring agent; metabolite |
| telmisartan | telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension. Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION. | benzimidazoles; biphenyls; carboxybiphenyl | angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic |
| benzamidine hydrochloride | |||
| tadalafil | benzodioxoles; pyrazinopyridoindole | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent | |
| marimastat | marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary | hydroxamic acid; secondary carboxamide | antineoplastic agent; matrix metalloproteinase inhibitor |
| 7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine | |||
| 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone | 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone: a cystic fibrosis transmembrane conductance regulator inhibitor; structure in first source | ||
| uccf-029 | organic heterotricyclic compound; organooxygen compound | ||
| quercetin | 7-hydroxyflavonol; pentahydroxyflavone | antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger | |
| apigenin | Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia. | trihydroxyflavone | antineoplastic agent; metabolite |
| rutin | Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders. | disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone | antioxidant; metabolite |
| genistein | 7-hydroxyisoflavones | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor | |
| paepalantine | paepalantine: an isocoumarin from Paepalanthus vellozioides; structure given in first source | ||
| vx-770 | ivacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis. ivacaftor: a CFTR potentiator; structure in first source | aromatic amide; monocarboxylic acid amide; phenols; quinolone | CFTR potentiator; orphan drug |
| lumacaftor | lumacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxylic acid with the aromatic amino group of 3-(6-amino-3-methylpyridin-2-yl)benzoic acid. Used for the treatment of cystic fibrosis. lumacaftor: a corrector of CF transmembrane conductance regulator (CTFR); structure in first source | aromatic amide; benzodioxoles; benzoic acids; cyclopropanes; organofluorine compound; pyridines | CFTR potentiator; orphan drug |
| 6-(3,5-difluoroanilino)-9-ethyl-2-purinecarbonitrile | 6-aminopurines | ||
| 6-(3,5-difluoroanilino)-9-(2,2-difluoroethyl)-2-purinecarbonitrile | 6-aminopurines | ||
| 9-(3,5-difluorophenyl)-6-(ethylamino)-2-purinecarbonitrile | imidazoles | ||
| grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source |